PA
TVTX icon

Perceptive Advisors’s Travere Therapeutics TVTX Stock Holding History

Perceptive Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123M Sell
4,142,551
-135,629
-3% -$4.05M 2.41% 12
2025
Q4 		$163M Buy
4,278,180
+483,565
+13% +$15.7M 2.91% 8
2025
Q3 		$90.7M Buy
3,794,615
+2,960,363
+355% +$55.7M 2.62% 11
2025
Q2 		$12.3M Buy
+834,252
New +$13.8M 0.46% 48
2024
Q1 		– Sell
-400,000
Closed -$3.6M – 125
2023
Q4 		$3.6M Hold
400,000
– – 0.08% 81
2023
Q3 		$3.58M Buy
400,000
+309,252
+341% +$4.36M 0.12% 77
2023
Q2 		$1.39M Hold
90,748
– – 0.04% 85
2023
Q1 		$2.04M Hold
90,748
– – 0.06% 89
2022
Q4 		$1.91M Hold
90,748
– – 0.05% 86
2022
Q3 		$2.24M Sell
90,748
-479,336
-84% -$12.4M 0.06% 102
2022
Q2 		$13.8M Sell
570,084
-1,275,471
-69% -$32.1M 0.43% 51
2022
Q1 		$47.6M Hold
1,845,555
– – 0.95% 27
2021
Q4 		$57.3M Sell
1,845,555
-120,000
-6% -$3.38M 0.88% 30
2021
Q3 		$47.7M Buy
1,965,555
+120,000
+7% +$2.2M 0.69% 35
2021
Q2 		$26.9M Sell
1,845,555
-1,452,864
-44% -$28.7M 0.35% 66
2021
Q1 		$82.4M Sell
3,298,419
-195,188
-6% -$5.39M 1.04% 26
2020
Q4 		$95.2M Buy
3,493,607
+253,495
+8% +$5.92M 1.02% 27
2020
Q3 		$59.8M Hold
3,240,112
– – 0.87% 31
2020
Q2 		$28.9M Buy
3,240,112
+349,504
+12% +$5.57M 0.47% 51
2020
Q1 		$42.2M Hold
2,890,608
– – 1.1% 20
2019
Q4 		$41M Sell
2,890,608
-379,963
-12% -$4.85M 0.82% 31
2019
Q3 		$37.9M Sell
3,270,571
-502,011
-13% -$8.3M 1.02% 27
2019
Q2 		$75.8M Buy
3,772,582
+717,875
+24% +$14.2M 1.74% 14
2019
Q1 		$69.1M Sell
3,054,707
-287,331
-9% -$6.35M 1.95% 13
2018
Q4 		$49.8M Buy
3,342,038
+129,167
+4% +$3.21M 1.89% 15
2018
Q3 		$60.5M Hold
3,212,871
– – 1.62% 20
2018
Q2 		$57.4M Hold
3,212,871
– – 1.5% 18
2018
Q1 		$71.8M Buy
3,212,871
+540,346
+20% +$12.9M 2.01% 13
2017
Q4 		$56.3M Sell
2,672,525
-13,679
-0.5% -$313K 1.87% 11
2017
Q3 		$66.9M Buy
2,686,204
+13,895
+0.5% +$306K 2.55% 8
2017
Q2 		$51.8M Sell
2,672,309
-135,216
-5% -$2.45M 2.61% 8
2017
Q1 		$51.8M Buy
2,807,525
+120,113
+4% +$2.35M 2.95% 8
2016
Q4 		$50.9M Buy
2,687,412
+240,930
+10% +$4.93M 3.62% 6
2016
Q3 		$54.8M Sell
2,446,482
-832,898
-25% -$15.9M 3.53% 5
2016
Q2 		$58.4M Buy
3,279,380
+280,000
+9% +$4.53M 4.05% 6
2016
Q1 		$41M Buy
2,999,380
+420,000
+16% +$6.37M 3.59% 6
2015
Q4 		$49.8M Sell
2,579,380
-67,700
-3% -$1.35M 3.68% 6
2015
Q3 		$53.6M Sell
2,647,080
-173,795
-6% -$5.15M 4.28% 4
2015
Q2 		$91.7M Buy
2,820,875
+35,895
+1% +$983K 5.52% 3
2015
Q1 		$66.7M Buy
2,784,980
+844,255
+44% +$12.9M 5.19% 3
2014
Q4 		$23.8M Buy
1,940,725
+561,588
+41% +$5.81M 1.99% 15
2014
Q3 		$12.4M Buy
1,379,137
+104,845
+8% +$1.23M 1.26% 24
2014
Q2 		$15M Buy
1,274,292
+230,000
+22% +$3.12M 1.47% 22
2014
Q1 		$22.1M Buy
+1,044,292
New +$16.1M 2.33% 11

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Perceptive Advisors's TVTX Position: Q1 2026 in Review

Perceptive Advisors reduced its Travere Therapeutics (TVTX) stake by 3.2% in Q1 2026, selling an estimated $4.05M and leaving 4,142,551 shares worth $123M. The position accounts for 2.41% of the portfolio, ranked #12.

Perceptive Advisors first reported a position in TVTX in Q1 2014 and has held it in 44 quarters since. The position peaked at $163M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Perceptive Advisors held 4,142,551 shares of Travere Therapeutics worth $123M as of Q1 2026.
  • Perceptive Advisors sold 135,629 Travere Therapeutics shares in Q1 2026, an estimated $4.05M.
  • Travere Therapeutics made up 2.41% of Perceptive Advisors's portfolio in Q1 2026, its #12 holding.
  • Perceptive Advisors first reported a position in Travere Therapeutics in Q1 2014 and has held it in 44 quarters since.
  • Perceptive Advisors's Travere Therapeutics position peaked at $163M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.